Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax, Ponatinib, and Dexamethasone in Ph+ ALL and CML
NCT03576547Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2018
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2018; status: terminated.
02
Drugs
venetoclax
03
Conditions
acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03576547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576547.